193 Prevalence of Swallowing Dysfunction in Severe Asthma: Preliminary Results

increased the time to first asthma deterioration thus decreasing the proportion of subjects experiencing asthma deterioration during the study (MF/F 1⁄4 16.5%; versus MF 1⁄4 28.2% [P 1⁄4 0.006]; versus F 1⁄4 44.7% [P , 0.001]; and vs placebo 1⁄4 45.7% [P , 0.001]). Mean FEV1 AUC0–12h over baseline at week 12 were MF/F 1⁄4 4.00 L · h; MF 1⁄4 2.53 L · h; F 1⁄4 3.83 L · h; and placebo 1⁄4 1.11 L · h. Low rates of AEs were observed and were similar between treatment arms. Conclusions: In asthmatics previously treated with low-dose ICS with or without a LABA, MF/F 100/10 mg BID was more effective than placebo, MF, or F (all administered by MDI) in reducing asthma deteriorations and improving lung function.